Defense Health Agency (DHA) OMNIBUS IV is a $10 billion indefinite delivery, indefinite quantity (IDIQ) multiple-award contract that provides for a broad range of health-related research and development and support services that are of interest to the Department of Defense (DoD) and the Military Healthcare System (MHS), across the continental United States and OCONUS.
UCS, a wholly-owned subsidiary of Tria Federal, has been awarded an IDIQ contract for the following market segments:
- Market Segment 1: Research & Development
- Market Segment 2: R&D Support Services
- Market Segment 4: Translational Science Support and Services
Task Order Types: Firm Fixed-Price, Cost-type, Time & Material/Labor Hours (T&M/LH).
Points of Contact
Primary:
Fabian Plath, Chief Growth Officer
Phone: 603.290.1688
Email: [email protected]
Secondary:
Phillip Bach, Associate General Counsel
Phone: 212.729.6432
Email: [email protected]